ZyVersa CEO Stephen Glover said, “ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with ...

Breaking bread is a powerful act of connection and shared moments, transcending barriers and bridging gaps. As we break bread we promote friendship, trust, and a sense of belonging.

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Studies by a growing number of labs have identified neurological health benefits from exposing human volunteers or animal ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Despite the rise in prescriptions, young Americans remain skeptical about semaglutide, preferring natural health habits and voicing strong concerns about media-fueled hype and safety risks.